



265 Industrial Way West, Ste. 7
Eatontown, NJ 07724-2213
Tel: (732) 982-8222 • Fax: (732) 982-8223
www.hapmarketing.com

NEWS RELEASE

Client: Gelest

Media contact: Mike Rubin
732-982-8238
mike.rubin@hapmarketing.com

For Immediate Release

Gelest Joins the Global Effort to Intensify Fight Against Antimicrobial Resistance

MORRISVILLE, Pa. (Aug 20, 2019) – Gelest, Inc., a leading innovator in materials science and the manufacturer of BIOSAFE® Antimicrobials, announced today that it has joined The Antimicrobial Resistance (AMR) Challenge launched by the U.S.

Government and CDC in September 2018. The AMR Challenge is an effort to accelerate the fight against antimicrobial resistance through committed action across governments and industries.

Antimicrobial resistance (AMR) occurs when bacteria, parasites, and fungi develop resistance against previously effective antimicrobials. AMR poses an increasingly serious threat to global public health that requires immediate action from government organizations, private companies, and society at large. In 2016, it was estimated that more than 700,000 people die each year due to drug-resistant infections. Without further action, infections caused by antimicrobial resistant “superbugs” could kill an additional 10 million people each year worldwide by 2050, overtaking cancer as one of the leading global causes of death.

“We are excited about joining this global effort and are committed to accelerating application development of our leading BIOSAFE® antimicrobial technology, which is highly effective and safe to use with minimal potential risk of creating adaptive resistant microorganisms,” said Ken Gayer, Chief Executive Officer of Gelest.

BIOSAFE® antimicrobials inhibit microorganism growth by physically puncturing the cell membrane, killing the microbes on contact by electrocuting them. This mode of action has been reported to have significantly less tendency for microbes to develop resistance through adaptation and mutation.

“We plan to launch a series of new products including antimicrobial laundry additives, surface cleaning wipes, wound care dressings, and more through partnership with private industries, governments, and non-governmental organizations worldwide,” said Gayer.

To learn more about Gelest BIOSAFE® antimicrobial technology, please email info@gelest.com. To view Gelest’s formal commitment to the AMR Challenge, please visit the [AMR Challenge website](#).

About Gelest

Gelest, Inc., a New Mountain Capital portfolio company headquartered in Morrisville, Pennsylvania, is an innovator, manufacturer, and supplier of silicones, organosilanes, and metal-organics for advanced technology end markets including medical devices, life sciences, microelectronics, and personal care. Gelest, Inc. helps customers succeed by assisting them to develop and supply the chemistry to solve their most challenging materials science problems and to enable their new product technology.

<https://www.gelest.com/>

About New Mountain Capital

New Mountain Capital is a New York based investment firm that emphasizes business building and growth rather than debt, as it pursues long-term capital appreciation. The firm currently manages private equity, public equity, and credit funds with over \$20 billion in assets under management. New Mountain seeks out what it believes to be the highest quality growth leaders in carefully selected industry sectors, working intensively with management to build the value of these companies. www.newmountaincapital.com

#